Amgen Issues Statement on Court of Appeals Ruling That Affirms Preliminary Injunction

Amgen Issues Statement on Court of Appeals Ruling That Affirms Preliminary Injunction Against Roche THOUSAND OAKS, Calif.--(Business Wire)-- Today the United States (U.S.) Court of Appeals for the Federal Circuit issued a ruling that affirms the preliminary injunction ordered by the U.S. District Court in Boston barring Roche from selling its pegylated-erythropoietin (peg-EPO) product MIRCERA in the U.S. Amgen (NASDAQ:AMGN) issued the following statement regarding today's ruling by the Court of Appeals: Amgen is pleased that the Court of Appeals has affirmed the preliminary injunction barring Roche from selling its peg-EPO product in the U.S. in violation of Amgen's erythropoietin (EPO) patents. Last week, the District Court ruled that Amgen is entitled to a permanent injunction and upheld the prior jury verdict and court... [read full story]